ADVERTISEMENT
3 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceutical Chemicals

India aims to be a global hub for drug production

by K. V. Venkatasubramanian, special to C&EN
April 18, 2020 | APPEARED IN VOLUME 98, ISSUE 15

 

India’s government has approved an initiative intended to make the country a global manufacturing hub for bulk drugs and medical devices. Initial funding for the project is ₹137.6 billion ($1.8 billion)—₹99.4 billion for bulk drugs and ₹38.2 billion for medical devices. The announcement came after the COVID-19 pandemic shut down manufacturing facilities and exports from China, where India gets much of its supply of key starting materials, drug intermediates, and active pharmaceutical ingredients. India’s effort will involve building three bulk-drug manufacturing parks in the next 5 years, each of which will have solvent recovery, distillation, and effluent treatment plants. In addition, the government will pay domestic drug manufacturers a 20% bonus on sales of 53 drugs deemed critical to the country. The government also plans to build four medical device manufacturing parks. The initiative—which India calls a production-linked investment scheme—will be implemented by a project management agency selected by the Department of Pharmaceuticals. The Indian Pharmaceutical Alliance, a trade group, welcomed the announcement, saying in a statement that the plan would promote health-care security in India.

C&EN has made this story and all of its coverage of the coronavirus epidemic freely available during the outbreak to keep the public informed. To support our journalism, become a member of ACS or sign up for C&EN's weekly newsletter.

CORRECTION

This story was updated on April 21, 2020, to correct the name of the trade group. It is the Indian Pharmaceutical Alliance, not the Indian Pharmaceutical Association.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment